268 related articles for article (PubMed ID: 36203609)
1. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
Signorelli D; Ghidotti P; Proto C; Brambilla M; De Toma A; Ferrara R; Galli G; Ganzinelli M; Lo Russo G; Prelaj A; Occhipinti M; Viscardi G; Capizzuto V; Pontis F; Petraroia I; Ferretti AM; Colombo MP; Torri V; Sozzi G; Garassino MC; Jachetti E; Fortunato O
Front Immunol; 2022; 13():987639. PubMed ID: 36203609
[TBL] [Abstract][Full Text] [Related]
2. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
6. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract][Full Text] [Related]
7. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
de Miguel-Perez D; Russo A; Arrieta O; Ak M; Barron F; Gunasekaran M; Mamindla P; Lara-Mejia L; Peterson CB; Er ME; Peddagangireddy V; Buemi F; Cooper B; Manca P; Lapidus RG; Hsia RC; Cardona AF; Naing A; Kaushal S; Hirsch FR; Mack PC; Serrano MJ; Adamo V; Colen RR; Rolfo C
J Exp Clin Cancer Res; 2022 Jun; 41(1):186. PubMed ID: 35650597
[TBL] [Abstract][Full Text] [Related]
9. Parallel SPR and QCM-D Quantitative Analysis of CD9, CD63, and CD81 Tetraspanins: A Simple and Sensitive Way to Determine the Concentration of Extracellular Vesicles Isolated from Human Lung Cancer Cells.
Kowalczyk A; Gajda-Walczak A; Ruzycka-Ayoush M; Targonska A; Mosieniak G; Glogowski M; Szumera-Cieckiewicz A; Prochorec-Sobieszek M; Bamburowicz-Klimkowska M; Nowicka AM; Grudzinski IP
Anal Chem; 2023 Jun; 95(25):9520-9530. PubMed ID: 37307147
[TBL] [Abstract][Full Text] [Related]
10. Circulating MicroRNAs and Extracellular Vesicle-Containing MicroRNAs as Response Biomarkers of Anti-programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC.
Shukuya T; Ghai V; Amann JM; Okimoto T; Shilo K; Kim TK; Wang K; Carbone DP
J Thorac Oncol; 2020 Nov; 15(11):1773-1781. PubMed ID: 32565389
[TBL] [Abstract][Full Text] [Related]
11. Small extracellular vesicles have distinct CD81 and CD9 tetraspanin expression profiles in plasma from rheumatoid arthritis patients.
Rydland A; Heinicke F; Flåm ST; Mjaavatten MD; Lie BA
Clin Exp Med; 2023 Oct; 23(6):2867-2875. PubMed ID: 36826611
[TBL] [Abstract][Full Text] [Related]
12. Enrichment of circulating tumor-derived extracellular vesicles from human plasma.
Yoh KE; Lowe CJ; Mahajan S; Suttmann R; Nguy T; Reichelt M; Yang J; Melendez R; Li Y; Molinero L; Ruppel J; Xu W; Plaks V
J Immunol Methods; 2021 Mar; 490():112936. PubMed ID: 33242493
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors.
Brocco D; Lanuti P; Pieragostino D; Cufaro MC; Simeone P; Bologna G; Di Marino P; De Tursi M; Grassadonia A; Irtelli L; De Lellis L; Veschi S; Florio R; Federici L; Marchisio M; Miscia S; Cama A; Tinari N; Del Boccio P
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546102
[TBL] [Abstract][Full Text] [Related]
14. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
15. Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments.
Stridfeldt F; Cavallaro S; Hååg P; Lewensohn R; Linnros J; Viktorsson K; Dev A
Talanta; 2023 Jul; 259():124553. PubMed ID: 37084607
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Brito ABC; Camandaroba MPG; de Lima VCC
Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
[TBL] [Abstract][Full Text] [Related]
17. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma.
Li JW; Shi D; Wan XC; Hu J; Su YF; Zeng YP; Hu ZJ; Yu BH; Zhang QL; Wei P; Zhou XY
Oncoimmunology; 2021; 10(1):1995166. PubMed ID: 34745768
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
Front Immunol; 2022; 13():951817. PubMed ID: 36263036
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer.
Dou X; Hua Y; Chen Z; Chao F; Li M
Clin Exp Immunol; 2022 May; 207(3):307-317. PubMed ID: 35553630
[TBL] [Abstract][Full Text] [Related]
20. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]